X4 Pharmaceuticals
About
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
- Cambridge,Massachusetts,United States
- 51 - 100
- https://www.x4pharma.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $55M
- Industries
- Biotechnology,Clinical Trials,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2014
- Number Of Employee
- 51 - 100
- Operating Status
- Active
- Stock Symbol
- nasdaq:XFOR
- Legal Name
- X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 7, 2022 | Post-IPO Equity | $65M | — | — | — | Detail |
| Jun 30, 2022 | Post-IPO Equity | $55M | 7 |
Acorn Bioventures
Lumira Ventures
New Enterprise Associates
|
— | Detail |
| Mar 19, 2021 | Post-IPO Equity | $55M | 9 | — | — | Detail |
| Nov 17, 2017 | IPO | — | — | — | — | Detail |
| Nov 16, 2017 | Series A | — | 1 | — | — | Detail |
Investments
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Acorn Bioventures
|
Yes | Post-IPO Equity |
|
Lumira Ventures
|
Yes | Post-IPO Equity |
|
New Enterprise Associates
|
Yes | Post-IPO Equity |
Cormorant Asset Management
|
Yes | Series B |
Hercules Capital
|
— | Post-IPO Equity |
|
|
— | Post-IPO Equity |
Bain Capital Life Sciences
|
— | Post-IPO Equity |
OrbiMed
|
— | Post-IPO Equity |
Abingworth
|
— | Post-IPO Equity |
Altium Capital
|
— | Post-IPO Equity |
Employee Profiles
